{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:35:20Z","timestamp":1787758520454,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The U.S. Food and Drug Administration (FDA) approved 6 CAR T cell (CAR-T) products, including tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), brexucabtagene autoleucel (brexu-cel), lisocabtagene maraleucel (liso-cel), idecabtagene vicleucel (ide-cel), and ciltacabtagene autoleucel (cilta-cel) in the last 5 years. CAR T-cell therapy significantly improved outcomes for patients with B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). However, recurrence and progression may occur after the initial response due to multiple mechanisms (Zeng and Zhang, 2022) [1]. Furthermore, CAR T-cell therapy is not broadly utilized in solid tumors due to various barriers. This review discusses the evolution of CAR T-cell therapies and how the \u201cyounger-generation\u201d CAR T cells counteract these challenges to potentially broaden their applications in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.56875\/2589-0646.1035","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T05:27:54Z","timestamp":1671686874000},"page":"117-121","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Next-Generation Chimeric Antigen Receptor T-cells"],"prefix":"10.4103","volume":"15","author":[{"given":"Dongni","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20241211","doi-asserted-by":"crossref","first-page":"112971","DOI":"10.1016\/j.yexcr.2021.112971","article-title":"Resistance and recurrence of malignancies after CAR-T cell therapy","volume":"410","author":"Zeng","year":"2022","journal-title":"Exp Cell Res"},{"key":"R2-7-20241211","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0021-9258(17)49904-2","article-title":"The structural basis of T- cell receptor (TCR) activation: an enduring enigma","volume":"295","author":"Mariuzza","year":"2020","journal-title":"J Biol Chem"},{"key":"R3-7-20241211","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-7-20241211","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor- derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"R5-7-20241211","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0960-9822(95)00175-8","article-title":"T-cell activation. Two for T","volume":"5","author":"Guerder","year":"1995","journal-title":"Curr Biol"},{"key":"R6-7-20241211","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"R7-7-20241211","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0092-8674(89)90943-4","article-title":"Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice","volume":"58","author":"Becker","year":"1989","journal-title":"Cell"},{"key":"R8-7-20241211","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-7-20241211","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"R10-7-20241211","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"R11-7-20241211","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third- generation CD19-specific CAR-T cells in B cell non-hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"R12-7-20241211","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/scisignal.aat6753","article-title":"Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function","volume":"11","author":"Salter","year":"2018","journal-title":"Sci Signal"},{"key":"R13-7-20241211","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"R14-7-20241211","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14712598.2018.1473368","article-title":"Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities","volume":"18","author":"Shum","year":"2018","journal-title":"Expet Opin Biol Ther"},{"key":"R15-7-20241211","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"R16-7-20241211","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R17-7-20241211","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: the fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expet Opin Biol Ther"},{"key":"R18-7-20241211","doi-asserted-by":"crossref","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","article-title":"Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4","volume":"285","author":"Wilkie","year":"2010","journal-title":"J Biol Chem"},{"key":"R19-7-20241211","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/mt.2014.47","article-title":"Reversal of tumor immune inhibition using a chimeric cytokine receptor","volume":"22","author":"Leen","year":"2014","journal-title":"Mol Ther"},{"key":"R20-7-20241211","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol Ther"},{"key":"R22-7-20241211","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"R23-7-20241211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1182\/blood.V97.1.63","article-title":"Administration of herpes simplex- thymidine kinase-expressing donor T cells with a T-cell- depleted allogeneic marrow graft","volume":"97","author":"Tiberghien","year":"2001","journal-title":"Blood"},{"key":"R24-7-20241211","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"R25-7-20241211","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \"safety switch\" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"R26-7-20241211","doi-asserted-by":"crossref","first-page":"755639","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Front Immunol"},{"key":"R27-7-20241211","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv Mar 12"},{"key":"R29-7-20241211","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","article-title":"The emerging landscape of immune cell therapies","volume":"181","author":"Weber","year":"2020","journal-title":"Cell"},{"key":"R30-7-20241211","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the- shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov Mar"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:16:49Z","timestamp":1787757409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.56875\/2589-0646.1035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.56875\/2589-0646.1035","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}